A Phase 1 interventional study of S-4321 in Autoimmune Diseases, Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA), sponsored by Seismic Therapeutic AU Pty Ltd. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Seismic Therapeutic AU Pty Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.
Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 133rd largest by planned enrollment of the 140 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 6 of the 20 other live ones, and was the 151st registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in Australia
Ages 18–75 · Healthy volunteers
The Bionics Institute of Australia · Sites in Australia
Ages 18–75
Candid Therapeutics · Sites in Australia
Ages 18–65 · Healthy volunteers
Kali Therapeutics, Inc. · Sites in Australia, New Zealand
Ages 18–75
Kali Therapeutics, Inc. · Sites in Australia
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 30 · Phase 3 72 · Phase 4 13
First in 2000; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 469 across the 140 interventional studies, 559 across the 13 observational. Of the 131 that completed or were terminated, 94 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 154 have an industry lead sponsor. The 10 most frequent:
Seismic Therapeutic AU Pty Ltd is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Seismic Therapeutic AU Pty Ltd has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
6 of the studies in Arthritis, Rheumatoid with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT07234773Kali Therapeutics, Inc.A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). | 2027-02 |
| NCT07207954Lifordi Immunotherapeutics, Inc.Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | 2027-07-16 |
| NCT07017686The Bionics Institute of AustraliaThe Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis | 2027-09 |
| NCT07455578Seismic Therapeutic AU Pty LtdStudy of S-4321 in Participants With an Autoimmune or Immune-mediated Disease | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in adults with autoimmune or immune-mediated disease including rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), cutaneous lupus erythematosus (CLE) with or without systemic manifestations, or atopic dermatitis (AD).
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
This study's planned enrollment of 24 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →Seismic Therapeutic AU Pty Ltd is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Compared within Arthritis, Rheumatoid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
All Participants Major Inclusion Criteria:
All Participants Major Exclusion Criteria:
Major inclusion/exclusion for each or immune-mediated disease:
For RA:
Confirmed diagnosis of moderate to severe active RA by the American College of Rheumatology (ACR) 2010/European League Against Rheumatism (EULAR) criteria for at least 3 months prior to the Screening 1 visit, and:
Inadequate response to, or loss of response, or intolerance to:
For PsA:
Confirmed diagnosis of adult-onset PsA classified by the Classification Criteria for Psoriatic Arthritis (CASPAR) for at least 3 months prior to the Screening 1 visit, with all of the following:
For PsO:
Confirmed diagnosis of moderate to severe plaque PsO for at least 6 months, with all of the following:
For CLE (with or without systemic manifestations):
For AD:
Confirmed diagnosis of AD as defined by the American Academy of Dermatology: Guidelines of Care for the Management of Atopic Dermatitis for at least 12 months
Inadequate response to existing topical medications within 6 months or has a history of intolerance to topical therapy as defined by at least 1 of the following:
Additional inclusion/exclusion criteria will apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SC Dose of S-4321
Drug: S-4321
Multiple doses of S-4321 via subcutaneous administration
Incidence of treatment-emergent adverse events (TEAEs)
Time frame: Through Week 31
Incidence of serious adverse events (SAEs)
Time frame: Through Week 31
Serum concentration of S-4321
Time frame: Through Week 28
Change from baseline in percent Receptor Occupancy (RO)
Time frame: Through Week 28
Change from baseline of soluble PD-1 (sPD-1)
Time frame: Through Week 28
Incidence of anti-drug antibodies (ADAs)
Time frame: Through Week 28
Plan to share: No — IPD sharing plan is not yet developed. Sponsor will consider data sharing at a later date.
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Sep 2027, 15 months later.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 15 months is above that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seismic Therapeutic AU Pty Ltd